Omeros (OMER) Expected to Post Earnings on Thursday

Omeros (NASDAQ:OMER) is projected to release its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of $0.02 per share and revenue of $37.28 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:30 PM ET.

Omeros (NASDAQ:OMER) last posted its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, analysts expect Omeros to post ($0.37) EPS for the current fiscal year and $1.21 EPS for the next fiscal year.

Omeros Stock Up 3.7%

OMER stock opened at $17.55 on Tuesday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 6.66 and a beta of 2.96. Omeros has a 12 month low of $6.24 and a 12 month high of $21.24. The firm has a 50 day moving average of $18.36 and a two-hundred day moving average of $13.62.

Insider Buying and Selling

In other news, Director Thomas J. Cable sold 15,000 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares in the company, valued at approximately $646,986.15. The trade was a 29.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter B. Cancelmo sold 25,000 shares of the business’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president owned 200 shares of the company’s stock, valued at $3,708. The trade was a 99.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 105,906 shares of company stock worth $1,989,705. 10.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on OMER shares. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright reissued a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $22.00 target price on shares of Omeros in a research report on Wednesday, October 14th. Finally, Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.